Pharmaron Beijing Co., Ltd. (FRA:17Q1)

Market Cap	6.18B +14.5%
Revenue (ttm)	1.62B +14.8%
Net Income	181.07M -19.7%
EPS	0.10 -19.4%
Shares Out	n/a
PE Ratio	34.11
Forward PE	23.65
Dividend	0.02 (1.07%)
Ex-Dividend Date	Jul 4, 2025

Volume	n/a
Average Volume	600
Open	2.160
Previous Close	2.220
Day's Range	2.160 - 2.160
52-Week Range	1.310 - 3.240
Beta	n/a
RSI	39.57
Earnings Date	Mar 31, 2026

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotide...

• Industry: Commercial Physical and Biological Research
• Founded: 2004
• Employees: 21,370
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 17Q1

Financial Performance

In 2024, Pharmaron Beijing's revenue was 12.28 billion, an increase of 6.39% compared to the previous year's 11.54 billion. Earnings were 1.79 billion, an increase of 12.01%.

Financial numbers in CNY